Consistent with previous observations in melanoma and other RAS-mutant cell lines, MEK inhibition with trametinib led to an increase in phospho-S6 and phospho-AKT (Figure 4C–4D, Supplementary Figure 4C–4D) [52, 71]. The gene discussed is AKT1; the disease is melanoma.